Stay updated on FT538 with Daratumumab in AML Clinical Trial
Sign up to get notified when there's something new on the FT538 with Daratumumab in AML Clinical Trial page.

Latest updates to the FT538 with Daratumumab in AML Clinical Trial page
- Check3 days agoChange DetectedA new page revision was added to the history: v3.3.4, replacing the prior revision v3.3.3. To avoid alerts for small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedFooter now shows Revision: v3.3.3. The HHS Vulnerability Disclosure and Revision: v3.3.2 links were removed.SummaryDifference0.2%

- Check53 days agoChange DetectedAdded Revision: v3.3.2 to the record history and removed Revision: v3.2.0. This is an administrative update to the page's versioning and does not alter study data or page content.SummaryDifference0.1%

- Check60 days agoChange DetectedDeleted a government funding notice about site operations. The core study history information remains unaffected.SummaryDifference0.7%

- Check74 days agoChange DetectedNew versions in the record history show updates to Study Status and Recruitment Status. The changes reflect the trial’s evolving state and its enrollment status.SummaryDifference0.2%

- Check103 days agoChange DetectedNew operating-status notice and version update to v3.2.0 are now present, replacing the previous v3.1.0; this adds important information about potential funding-related service limitations and where to check for status.SummaryDifference12%

Stay in the know with updates to FT538 with Daratumumab in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FT538 with Daratumumab in AML Clinical Trial page.